885461-10-9

Upstream product

• 529-28-2 4-iodoanisol 

Downstream Products

• 871822-60-5 (2S)-{2-[5-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-sulfamoylbiphenyl-3-yl]-2-methylpropionylamino}succinamide 
• 731015-35-3 2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6,2'-dihydroxy-5'-sulfamoylbiphenyl-3-yl]-2-methylpropionic acid 
• 718603-63-5 N-tert-butyl-3-iodo-4-methoxybenzenesulfonamide 
• 731016-02-7 N-tert-butyl-2-methoxy-5-(benzenesulfonamido)boronic acid 
• 871266-66-9 methyl [5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-2′-methoxy-5′-sulfamoylbiphenyl-3-yl]acetate 
• 871266-67-0 dibenzyl (S)-2-{2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6,2'-dihydroxy-5'-sulfamoylbiphenyl-3-yl]acetylamino}succinate 
• 871266-65-8 methyl [5'-N-tert-butylsulfamoyl-5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-2'-methoxybiphenyl-3-yl]acetate 

Relevant academic research and scientific papers

FACTOR VIIA INHIBITOR

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.

FACTOR VIIA INHIBITOR

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders